EFFECTS OF RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES IN NEW ONSET SUBJECTS

利妥昔单抗对新发受试者 1 型糖尿病进展的影响

• 批准号: 7951724
• 负责人: JOHN A WAGNER
• 金额: $ 0.4万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951724
• 关键词: B-Lymphocytes; Beta Cell; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Dependence; Diabetes Mellitus; Disease; Funding; Grant; Immune; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; Life; Mediating; Research; Research Personnel; Resources; Source; United States National Institutes of Health; prevent; rituximab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Type 1 diabetes mellitus is an immune-mediated disease in which insulin-producing beta cells are completely destroyed resulting in life-long dependence on exogenous insulin. We hypothesize that rituximab, by eliminating B cells, would be effective at halting beta cell destruction thereby preventing the progression of diabetes.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 1型糖尿病是一种免疫介导的疾病，其中产生胰岛素的β细胞被完全破坏，导致终身依赖外源性胰岛素。我们假设利妥昔单抗通过消除B细胞，将有效阻止β细胞破坏，从而防止糖尿病的进展。